Find out the direct holders, institutional holders and mutual fund holders for Aileron Therapeutics, Inc. (ALRN).What's Happening With ALRN Stock Today? More About Aileron Therapeutics Inc Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases.What's Happening With ALRN Stock Today? Aileron Therapeutics Inc (ALRN) stock is trading at $1.30 as of 12:12 PM on Tuesday, Feb 21, a decline of -$1.08, or -45.38% from the previous closing price of $2.38. The stock has traded between $1.29 and $1.58 so far today. Volume today is more active than usual.ALRN Earnings Date and Information. Aileron Therapeutics last issued its quarterly earnings results on August 11th, 2023. The reported ($0.39) earnings per share for the quarter. Aileron Therapeutics has generated $0.00 earnings per share over the last year. Aileron Therapeutics has not formally confirmed its next earnings publication date, but ...The Aileron Therapeutics stock forecast for tomorrow is $ 1.643067, which would represent a -0.42% loss compared to the current price. In the next week, the price of ALRN is expected to increase by 3.16% and hit $ 1.702099. As far as the long-term Aileron Therapeutics stock forecast is concerned ... Aileron Therapeutics Inc. analyst estimates, including ALRN earnings per share estimates and analyst recommendations.ALRN Stock Price Chart Interactive Chart > Aileron Therapeutics, Inc. (ALRN) Company Bio Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are ...ALRN-6924 Breast Cancer Trial Design. We are currently conducting a clinical trial of ALRN-6924 in patients with p53-mutated breast cancer. The Phase 1b, open-label, single-arm, multicenter trial is designed to evaluate the safety, tolerability and chemoprotective effect of ALRN-6924 in up to 24 patients with p53-mutated breast cancer undergoing either neoadjuvant or adjuvant treatment with ... Sep 7, 2023 · The Aileron Therapeutics Inc stock price fell by -4.24% on the last day (Thursday, 7th Sep 2023) from $1.65 to $1.58. During the last trading day the stock fluctuated 5.77% from a day low at $1.56 to a day high of $1.65. The price has risen in 4 of the last 10 days and is up by 0.7% over the past 2 weeks. Volume has increased on the last day by ... ALRN : Aileron Therapeutics stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical AnalysisAileron Therapeutics, Inc. (ALRN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6099 -0.0001 (-0.01%) As of 03:20PM EDT. Market open. 1d. After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in ...Price. ALRN. 1.660. 0.00%. Webull offers kinds of Aileron Therapeutics Inc stock information, including NASDAQ:ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions. Jan 5, 2021 · ALRN Stock Is a Bet on Chemoprotection Treatment. Next month, the company expects to reach a critical milestone in the development of its chemoprotection treatment, ... ALRN-6924 Breast Cancer Trial Design. We are currently conducting a clinical trial of ALRN-6924 in patients with p53-mutated breast cancer. The Phase 1b, open-label, single-arm, multicenter trial is designed to evaluate the safety, tolerability and chemoprotective effect of ALRN-6924 in up to 24 patients with p53-mutated breast cancer undergoing either neoadjuvant or adjuvant treatment with ...Aug 22, 2023 · ALRN stock returns are also predicted based on historical data. According to our research, ALRN stock is a bad long-term investment. ALRN share price has been in a bear cycle for the past year. Find the latest Aileron Therapeutics, Inc. (ALRN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. galaxy worldmagically Sep 1, 2023 · Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. Shares of Aileron Therapeutics (NASDAQ: ALRN) were up on Tuesday morning, joining general speculation in biotech and pharmaceutical names. ALRN stock was up more than 25% at 10 a.m. Eastern ...Mar 14, 2023 · Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ... After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in ...As Aileron Therapeutics, Inc.'s market cap (NASDAQ:ALRN) drops to US$47m, insiders might be questioning their decision to buy earlier this year. (Simply Wall St.) Dec-20-21 10:56AM. Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs.Find out the direct holders, institutional holders and mutual fund holders for Aileron Therapeutics, Inc. (ALRN).Get Aileron Therapeutics Inc (ALRN.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... ALRN-6924 can pause cell division in ...After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Aileron Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ...View the latest Aileron Therapeutics Inc. (ALRN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Sep 8, 2023 · Stock Price Statistics The stock price has decreased by -54.68% in the last 52 weeks. The beta is 2.12, so ALRN's price volatility has been higher than the market average. Aileron Therapeutics Inc (ALRN) Stock Price & News - Google Finance Home ALRN • NASDAQ Aileron Therapeutics Inc Follow Share $1.58 Sep 8, 8:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer search... Feb 21, 2023 · These Healthcare stocks are trading lower: -CVRx Inc ( CVRX) stock is trading at $7.00, a decline of $10.2, or 59.36%, on high volume. CVRx Inc. gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $19.20. -Aileron Therapeutics Inc ( ALRN) stock is trading ... The latest Aileron Therapeutics stock prices, stock quotes, news, and ALRN history to help you invest and trade smarter. ... It focuses on its lead product candidate, ALRN-6924, which is a cell ... goojara movie Aileron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022. Nov. 01. CI. Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for ... Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ...Aileron Therapeutics Inc. Watch list Closed Last Updated: Sep 8, 2023 3:53 p.m. EDT Delayed quote $ 1.5801 0.0001 0.01% Previous Close $1.5800 Advanced Charting Volume: 6.52K 65 Day Avg: 20.84K 31%...ALRN | Aileron Therapeutics Inc. Stock Overview (U.S.: Nasdaq) | Barron's Market Data / Stocks / ALRN / Overview Aileron Therapeutics Inc. U.S.: Nasdaq after hours $ 1.6100 ALRN 0.00...Why That Explains a Mysterious Medtech Stock Selloff. ... ALRN Profile. Company Profile. Aileron Therapeutics Inc. 738 Main Street. No. 398. Waltham, Massachusetts 02451 . Phone 1 617 995-0900.Aileron Therapeutics Inc (ALRN) Company Description. Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells ...Aileron Therapeutics (ALRN) (Delayed Data from NSDQ) $1.57 USD +0.01 (0.58%) Updated Aug 23, 2023 03:56 PM ET Add to portfolio Zacks Rank: 3-Hold 3 Style Scores: D Value | C Growth | C Momentum...Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b ...The Amarin Corporation PLC stock price fell by -0.98% on the last day (Friday, 8th Sep 2023) from $1.02 to $1.01. During the last trading day the stock fluctuated 2.00% from a day low at $1.00 to a day high of $1.02. The price has been going up and down for this period, and there has been a -1.94% loss for the last 2 weeks. seeking a friend for the end of the world Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers.Sep 1, 2023 · Aileron Therapeutics stock was originally listed at a price of $216.00 in Jun 29, 2017. If you had invested in Aileron Therapeutics stock at $216.00, your return over the last 6 years would have been -99.23%, for an annualized return of -55.58% (not including any dividends or dividend reinvestments). Gary Gelman ALRN stock SEC Form 4 insiders trading Gary has made over 5 trades of the Aileron Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Gary bought 1,000,000 units of ALRN stock worth $2,000,000 on 3 January 2012 .Gary Gelman ALRN stock SEC Form 4 insiders trading Gary has made over 5 trades of the Aileron Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Gary bought 1,000,000 units of ALRN stock worth $2,000,000 on 3 January 2012 .A high-level overview of Aileron Therapeutics, Inc. (ALRN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.ALRN stock returns are also predicted based on historical data. According to our research, ALRN stock is a bad long-term investment. ALRN share price has been in a bear cycle for the past year.Why That Explains a Mysterious Medtech Stock Selloff. ... ALRN Profile. Company Profile. Aileron Therapeutics Inc. 738 Main Street. No. 398. Waltham, Massachusetts 02451 . Phone 1 617 995-0900.Sep 12, 2023 · A high-level overview of Aileron Therapeutics, Inc. (ALRN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Aileron Therapeutics Inc. analyst estimates, including ALRN earnings per share estimates and analyst recommendations.Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test ...Feb 17, 2023 · ... Read More. Powered by Nasdaq Data Link News What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock Zacks • Dec 29, 2022 Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon,... Jul 21, 2019 · Gary Gelman ALRN stock SEC Form 4 insiders trading Gary has made over 5 trades of the Aileron Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Gary bought 1,000,000 units of ALRN stock worth $2,000,000 on 3 January 2012 . Jul 21, 2019 · Gary Gelman ALRN stock SEC Form 4 insiders trading Gary has made over 5 trades of the Aileron Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Gary bought 1,000,000 units of ALRN stock worth $2,000,000 on 3 January 2012 . Morningstar‘s Stock Analysis ALRN Summary Competitors Valuation Jul 5, 2023Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test ...Zacks Equity Research. November 4, 2022 at 12:00 PM · 4 min read. Aileron Therapeutics, Inc. (ALRN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This ... mastery connect What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock 12/29/22-11:00AM EST Zacks Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAileron Therapeutics Inc (ALRN) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.Aileron Therapeutics Inc (ALRN) stock has risen 70.59% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.Sep 13, 2023 · ALRN Earnings Date and Information. Aileron Therapeutics last issued its quarterly earnings results on August 11th, 2023. The reported ($0.39) earnings per share for the quarter. Aileron Therapeutics has generated $0.00 earnings per share over the last year. Aileron Therapeutics has not formally confirmed its next earnings publication date, but ... ALRN-6924 Breast Cancer Trial Design. We are currently conducting a clinical trial of ALRN-6924 in patients with p53-mutated breast cancer. The Phase 1b, open-label, single-arm, multicenter trial is designed to evaluate the safety, tolerability and chemoprotective effect of ALRN-6924 in up to 24 patients with p53-mutated breast cancer undergoing either neoadjuvant or adjuvant treatment with ... dating apps for teens The company’s shares closed last Tuesday at $0.66. According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 4Multiple upgrades post earnings JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. Stock Price Statistics. The stock price has decreased by -54.68% in the last 52 weeks. The beta is 2.12, so ALRN's price volatility has been higher than the market average.Sep 15, 2022 · Aileron Therapeutics Inc (ALRN) stock has risen 70.59% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. May 19, 2022 · Check out our ALRN stock analysis, current ALRN quote, charts, and historical prices for Aileron Therapeutics Inc stock Aileron Therapeutics launches ALRN-6924 trial in patients with advanced non-small cell lung cancer. SA NewsThu, Jul. 01, 2021.The latest price target for Aileron Therapeutics ( NASDAQ: ALRN) was reported by HC Wainwright & Co. on Thursday, June 30, 2022. The analyst firm set a price target for 1.00 expecting ALRN to fall ...Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022. BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its common stock.The company’s shares closed last Tuesday at $0.66. According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 4Multiple upgrades post earnings JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00.ALRN stock returns are also predicted based on historical data. According to our research, ALRN stock is a bad long-term investment. ALRN share price has been in a bear cycle for the past year. samyakk Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers.Shares of Aileron Therapeutics (NASDAQ: ALRN) were up on Tuesday morning, joining general speculation in biotech and pharmaceutical names. ALRN stock was up more than 25% at 10 a.m. Eastern ...... Read More. Powered by Nasdaq Data Link News What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock Zacks • Dec 29, 2022 Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon,...Year 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027; Revenue ----- casper humane society Find the latest Aileron Therapeutics, Inc. (ALRN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers.Analysts who follow Aileron Therapeutics Inc (ALRN) on average expect it to rise 733.33% over the next twelve months. Those same analysts give the stock an average rating of Buy. gunrun May 8, 2023 · Aileron Therapeutics Inc stock is lower by -81.76% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives ALRN stock a score of 7 out of a possible 100. Shares of Aileron Therapeutics (NASDAQ: ALRN) were up on Tuesday morning, joining general speculation in biotech and pharmaceutical names. ALRN stock was up more than 25% at 10 a.m. Eastern ...Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers.Aileron Therapeutics Inc. Watch list Closed Last Updated: Sep 8, 2023 3:53 p.m. EDT Delayed quote $ 1.5801 0.0001 0.01% Previous Close $1.5800 Advanced Charting Volume: 6.52K 65 Day Avg: 20.84K 31%...Aileron Therapeutics Inc (ALRN) stock has fallen -9.23% while the S&P 500 is higher by 4.5% as of 11:31 AM on Thursday, Nov 10. ALRN has fallen -$0.02 from the previous closing price of $0.18 on volume of 967,496 shares. Over the past year the S&P 500 is lower by -16.39% while ALRN has fallen -81.52%.Analysts who follow Aileron Therapeutics Inc (ALRN) on average expect it to rise 733.33% over the next twelve months. Those same analysts give the stock an average rating of Buy.Aileron Therapeutics Inc (ALRN) stock has fallen -9.23% while the S&P 500 is higher by 4.5% as of 11:31 AM on Thursday, Nov 10. ALRN has fallen -$0.02 from the previous closing price of $0.18 on volume of 967,496 shares. Over the past year the S&P 500 is lower by -16.39% while ALRN has fallen -81.52%.Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.Morningstar‘s Stock Analysis ALRN Summary Competitors Valuation Jul 5, 2023The estimated Net Worth of Rick Wanstall is at least $85.2 Thousand dollars as of 25 May 2022. Mr. Wanstall owns over 3,777 units of Aileron Therapeutics Inc stock worth over $85,170 and over the last 4 years he sold ALRN stock worth over $0. In addition, he makes $0 as Chief Financial Officer and Treasurer at Aileron Therapeutics Inc.5 analysts have issued twelve-month price objectives for Vertex Energy's shares. Their VTNR share price forecasts range from $6.90 to $15.00. On average, they anticipate the company's stock price to reach $9.57 in the next year. This suggests a possible upside of 103.5% from the stock's current price. View analysts price targets for VTNR or ...As Aileron Therapeutics, Inc.'s market cap (NASDAQ:ALRN) drops to US$47m, insiders might be questioning their decision to buy earlier this year. (Simply Wall St.) Dec-20-21 10:56AM. Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs. Feb 21, 2023 · What's Happening With ALRN Stock Today? Aileron Therapeutics Inc (ALRN) stock is trading at $1.30 as of 12:12 PM on Tuesday, Feb 21, a decline of -$1.08, or -45.38% from the previous closing price of $2.38. The stock has traded between $1.29 and $1.58 so far today. Volume today is more active than usual. taylor mathis Sep 1, 2023 · Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more ...Aileron Therapeutics, Inc. (ALRN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6099 -0.0001 (-0.01%) As of 03:20PM EDT. Market open. 1d. Aileron Therapeutics Inc. analyst estimates, including ALRN earnings per share estimates and analyst recommendations. ALRN | Aileron Therapeutics Inc. Stock Overview (U.S.: Nasdaq) | Barron's Market Data / Stocks / ALRN / Overview Aileron Therapeutics Inc. U.S.: Nasdaq after hours $ 1.6100 ALRN 0.00... A downtrend has been apparent in Aileron Therapeutics, Inc. (ALRN) lately. While the stock has lost 14.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed ...Sep 13, 2023 · 5 analysts have issued twelve-month price objectives for Vertex Energy's shares. Their VTNR share price forecasts range from $6.90 to $15.00. On average, they anticipate the company's stock price to reach $9.57 in the next year. This suggests a possible upside of 103.5% from the stock's current price. View analysts price targets for VTNR or ... The Trend in the Analyst Price Target. Over the past 29 months, ALRN's average price target has gone up $35. ALRN reports an average of 5,467.91% for its upside potential over the past 0 secs. Date. Number of Analysts. Shares of Aileron Therapeutics (NASDAQ: ALRN) were up on Tuesday morning, joining general speculation in biotech and pharmaceutical names. ALRN stock was up more than 25% at 10 a.m. Eastern ...What's Happening With ALRN Stock Today? More About Aileron Therapeutics Inc Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases.ALRN stock returns are also predicted based on historical data. According to our research, ALRN stock is a bad long-term investment. ALRN share price has been in a bear cycle for the past year. converter sek usd Apr 4, 2023 · Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher by Zacks Equity Research Published on October 13,2020 Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped ... Sep 8, 2023 · Stock Price Statistics The stock price has decreased by -54.68% in the last 52 weeks. The beta is 2.12, so ALRN's price volatility has been higher than the market average. 5 analysts have issued twelve-month price objectives for Vertex Energy's shares. Their VTNR share price forecasts range from $6.90 to $15.00. On average, they anticipate the company's stock price to reach $9.57 in the next year. This suggests a possible upside of 103.5% from the stock's current price. View analysts price targets for VTNR or ...Jan 5, 2021 · ALRN Stock Is a Bet on Chemoprotection Treatment. Next month, the company expects to reach a critical milestone in the development of its chemoprotection treatment, ... Aileron Therapeutics Inc. analyst estimates, including ALRN earnings per share estimates and analyst recommendations. Price. ALRN. 1.660. 0.00%. Webull offers kinds of Aileron Therapeutics Inc stock information, including NASDAQ:ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions. What's Happening With ALRN Stock Today? To see InvestorsObserver's Sentiment Score for Aileron Therapeutics Inc click here. More About Aileron Therapeutics Inc Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases.Apr 4, 2023 · Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher by Zacks Equity Research Published on October 13,2020 Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped ... ALRN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Aileron Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALRN!What's Happening With ALRN Stock Today? Aileron Therapeutics Inc (ALRN) stock is trading at $1.30 as of 12:12 PM on Tuesday, Feb 21, a decline of -$1.08, or -45.38% from the previous closing price of $2.38. The stock has traded between $1.29 and $1.58 so far today. Volume today is more active than usual.ALRN Stock Is a Bet on Chemoprotection Treatment. Next month, the company expects to reach a critical milestone in the development of its chemoprotection treatment, ...View the latest Aileron Therapeutics Inc. (ALRN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Aileron Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ... wlds ALRN Earnings Date and Information. Aileron Therapeutics last issued its quarterly earnings results on August 11th, 2023. The reported ($0.39) earnings per share for the quarter. Aileron Therapeutics has generated $0.00 earnings per share over the last year. Aileron Therapeutics has not formally confirmed its next earnings publication date, but ...Find the latest Aileron Therapeutics, Inc. (ALRN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Mar 14, 2023 · Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ... ALRN received an overall rating of 51, which means that it scores higher than 51 percent of all stocks. Aileron Therapeutics Inc also achieved a score of 73 in the Biotechnology industry, putting it above 73 percent of Biotechnology stocks. cheap flights austin Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy.Mar 14, 2023 · Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ... Apr 4, 2023 · Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher by Zacks Equity Research Published on October 13,2020 Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped ... After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data ...ALRN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Aileron Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALRN!Oct 26, 2021 · ALRN : Aileron Therapeutics stock forecast, predictions, and share price target for 2022, 2023 (1 year) to 2025 - 2027 (5 year) to 2030, and 2032 (10 year) with Revenue and EPS Prognosis by Technical Analysis Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test ...Oct 26, 2022 · ALRN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Aileron Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALRN! the raid The latest price target for Aileron Therapeutics ( NASDAQ: ALRN) was reported by HC Wainwright & Co. on Thursday, June 30, 2022. The analyst firm set a price target for 1.00 expecting ALRN to fall ...Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.The latest Aileron Therapeutics stock prices, stock quotes, news, and ALRN history to help you invest and trade smarter. ... It focuses on its lead product candidate, ALRN-6924, which is a cell ...Aileron Therapeutics Inc (ALRN) Stock Price & News - Google Finance Home ALRN • NASDAQ Aileron Therapeutics Inc Follow Share $1.58 Sep 8, 8:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer search... What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock Zacks - Thu Dec 29, 2022 . Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. petexec Aileron Therapeutics (ALRN) Stock Forecast & Price TargetAileron Therapeutics Inc (ALRN) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Aileron Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ...Apr 5, 2022 · Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year. como funciona paypal Price. ALRN. 1.660. 0.00%. Webull offers kinds of Aileron Therapeutics Inc stock information, including NASDAQ:ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions.The company’s shares closed last Tuesday at $0.66. According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 4Multiple upgrades post earnings JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. Price. ALRN. 1.660. 0.00%. Webull offers kinds of Aileron Therapeutics Inc stock information, including NASDAQ:ALRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALRN stock news, and many more online research tools to help you make informed decisions. time simplicity The Trend in the Broker Recommendations. ALRN's average broker recommendation rating worsened by 0.66 over the prior 153 days. The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ALRN as an investment opportunity.Aug 22, 2023 · ALRN stock returns are also predicted based on historical data. According to our research, ALRN stock is a bad long-term investment. ALRN share price has been in a bear cycle for the past year. Aileron Therapeutics Inc (ALRN) Company Description. Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells ...Sep 1, 2023 · Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b ... The estimated Net Worth of Rickenbach Josef H Von is at least $713 Thousand dollars as of 8 June 2020. Mr. Von owns over 227,272 units of Aileron Therapeutics Inc stock worth over $712,736 and over the last 7 years he sold ALRN stock worth over $0. In addition, he makes $0 as Independent Director at Aileron Therapeutics Inc.Sep 20, 2022 · Analysts who follow Aileron Therapeutics Inc (ALRN) on average expect it to rise 733.33% over the next twelve months. Those same analysts give the stock an average rating of Buy. ALRN Stock Is a Bet on Chemoprotection Treatment. Next month, the company expects to reach a critical milestone in the development of its chemoprotection treatment, ...Aileron Therapeutics Inc (ALRN) stock has risen 70.59% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. buc ee's alabama After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data ...ALRN-6924. We use a biomarker-driven approach to protect against chemotherapy-induced side effects. ALRN-6924 is a novel medicine designed to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy’s destruction of cancer cells.Dec 28, 2018 · 10/31/19 8:42 AM. Post #11. WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m. ET on Thursday, November 7, 2019 to report its third quarter ... Aileron Therapeutics Inc (ALRN) stock has risen 1.83% while the S&P 500 is lower by -0.08% as of 10:38 AM on Monday, May 8. ALRN has gained $0.02 from the previous closing price of $1.37 on volume of 2,822 shares. Over the past year the S&P 500 has risen 3.55% while ALRN is lower by -81.76%.What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock 12/29/22-11:00AM EST Zacks Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now magazine luiza cred Our common stock is listed on the Nasdaq Capital Market under the symbol “ALRN.” On June 2, 2020, the last reported sale price of our common stock on the Nasdaq Capital Mark. 2020-06-03: 424B5: Common StockSep 13, 2023 · ALRN Earnings Date and Information. Aileron Therapeutics last issued its quarterly earnings results on August 11th, 2023. The reported ($0.39) earnings per share for the quarter. Aileron Therapeutics has generated $0.00 earnings per share over the last year. Aileron Therapeutics has not formally confirmed its next earnings publication date, but ... Sep 12, 2023 · A high-level overview of Aileron Therapeutics, Inc. (ALRN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 98.5 kygo Aileron Therapeutics (ALRN) Stock Forecast & Price Target The estimated Net Worth of Rickenbach Josef H Von is at least $713 Thousand dollars as of 8 June 2020. Mr. Von owns over 227,272 units of Aileron Therapeutics Inc stock worth over $712,736 and over the last 7 years he sold ALRN stock worth over $0. In addition, he makes $0 as Independent Director at Aileron Therapeutics Inc.Shares of Aileron Therapeutics (NASDAQ: ALRN) were up on Tuesday morning, joining general speculation in biotech and pharmaceutical names. ALRN stock was up more than 25% at 10 a.m. Eastern ...Aileron Therapeutics Inc. analyst estimates, including ALRN earnings per share estimates and analyst recommendations. Morningstar‘s Stock Analysis ALRN Summary Competitors Valuation Jul 5, 2023ALRN Stock Message Board for Investors. American Learning Corp. Stock Price, News and Company Updates. Message Board Total Posts: 32Mar 10, 2021 · That average ranking earns the stock an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver. Wall Street analysts are rating ALRN a Strong Buy today. Find out what this means to you and get the rest of the rankings on ALRN! As of 2023 September 12, Tuesday current price of ALRN stock is 1.590$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). Aileron Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame.Jan 8, 2021 · Aileron Therapeutics Inc (ALRN) stock is trading at $1.34 as of 3:12 PM on Friday, Jan 8, an increase of $0.11, or 9.01% from the previous closing price of $1.23. The stock has traded between $1.23 and $1.41 so far today. Volume today is above average. mapmyride Apr 12, 2023 · What's Happening With ALRN Stock Today? More About Aileron Therapeutics Inc Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. ALRN-6924 Breast Cancer Trial Design. We are currently conducting a clinical trial of ALRN-6924 in patients with p53-mutated breast cancer. The Phase 1b, open-label, single-arm, multicenter trial is designed to evaluate the safety, tolerability and chemoprotective effect of ALRN-6924 in up to 24 patients with p53-mutated breast cancer undergoing either neoadjuvant or adjuvant treatment with ... The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock. ABR vs Zacks Rank. 3.00. ABR (Last week) 3.00. # of Recs ...Analysts who follow Aileron Therapeutics Inc (ALRN) on average expect it to rise 733.33% over the next twelve months. Those same analysts give the stock an average rating of Buy.Sep 14, 2023 · Aileron Therapeutics launches ALRN-6924 trial in patients with advanced non-small cell lung cancer. SA NewsThu, Jul. 01, 2021. vika These Healthcare stocks are trading lower: -CVRx Inc ( CVRX) stock is trading at $7.00, a decline of $10.2, or 59.36%, on high volume. CVRx Inc. gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $19.20. -Aileron Therapeutics Inc ( ALRN) stock is trading ...Aileron Therapeutics Inc (ALRN) stock is trading at $1.34 as of 3:12 PM on Friday, Jan 8, an increase of $0.11, or 9.01% from the previous closing price of $1.23. The stock has traded between $1.23 and $1.41 so far today. Volume today is above average.Aug 24, 2023 · AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Aileron Therapeutics Inc’s stock grades for value, growth and quality. What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock msn.com - December 29 at 1:22 PM: Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements finance.yahoo.com - November 30 at 8:00 AM: Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now finance.yahoo.com - November 24 at 1 ...ALRN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Aileron Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALRN!Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022. BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its common stock.